IMMP
Immutep Receives A$2.7 million R&D Tax Incentive from French Government
Thursday, September 22, 2022 BiopharmaWatch Research 1 min read Key Takeaway: Immutep Receives A$2.7 million R&D Tax Incentive from French Government
Price reaction · baseline $1.84 (2022-09-21 close) · hit after-hours · 2 other IMMP headline(s) in the window, move may be shared
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+76%
120-day peak, hindsight
Typical move
5.4%
average across 13 past catalysts
Lead asset
eftilagimod alfa
Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Full Press Release Details
Immutep Receives A$2.7 million R&D Tax Incentive from French Government.